$271 Million is the total value of Artia Global Partners LP's 36 reported holdings in Q1 2023. The portfolio turnover from Q4 2022 to Q1 2023 was 233.3% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| MRK | Buy | MERCK & CO INC | $35,023,588 | +19.5% | 329,200 | +24.6% | 12.94% | +15.9% |
| BIIB | Buy | BIOGEN INC | $22,242,400 | +167.7% | 80,000 | +166.7% | 8.22% | +159.6% |
| MRNA | Buy | MODERNA INC | $13,011,144 | -3.1% | 84,719 | +13.4% | 4.81% | -6.0% |
| BMRN | Buy | BIOMARIN PHARMACEUTICAL INC | $11,519,537 | +294.5% | 118,465 | +319.8% | 4.26% | +282.5% |
| New | SAREPTA THERAPEUTICS INCcall | $8,269,800 | – | 60,000 | +100.0% | 3.06% | – | |
| New | NOVO-NORDISK A Scall | $7,957,000 | – | 50,000 | +100.0% | 2.94% | – | |
| AZN | Buy | ASTRAZENECA PLCsponsored adr | $7,101,129 | +34.7% | 102,307 | +31.6% | 2.62% | +30.6% |
| New | KARUNA THERAPEUTICS INCput | $5,449,200 | – | 30,000 | +100.0% | 2.01% | – | |
| RETA | New | REATA PHARMACEUTICALS INCcl a | $3,636,800 | – | 40,000 | +100.0% | 1.34% | – |
| VRNA | Buy | VERONA PHARMA PLCsponsored ads | $1,816,256 | +74.0% | 90,451 | +126.4% | 0.67% | +68.6% |
| CBAY | New | CYMABAY THERAPEUTICS INC | $1,476,095 | – | 169,277 | +100.0% | 0.54% | – |
| CRL | New | CHARLES RIV LABS INTL INC | $1,393,567 | – | 6,905 | +100.0% | 0.52% | – |
| New | ROIVANT SCIENCES LTD | $1,164,291 | – | 157,763 | +100.0% | 0.43% | – | |
| FGEN | New | FIBROGEN INC | $966,495 | – | 51,795 | +100.0% | 0.36% | – |
| PCVX | New | VAXCYTE INC | $853,007 | – | 22,759 | +100.0% | 0.32% | – |
| New | TYRA BIOSCIENCES INC | $727,216 | – | 45,253 | +100.0% | 0.27% | – | |
| New | ALTIMMUNE INCcall | $422,000 | – | 100,000 | +100.0% | 0.16% | – | |
| AMRN | New | AMARIN CORP PLCspons adr new | $385,200 | – | 256,800 | +100.0% | 0.14% | – |
| LEGN | New | LEGEND BIOTECH CORPsponsored ads | $241,100 | – | 5,000 | +100.0% | 0.09% | – |
| LRMR | New | LARIMAR THERAPEUTICS INC | $172,398 | – | 38,057 | +100.0% | 0.06% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2023-05-15
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| NOVO-NORDISK A S | 4 | Q3 2023 | 25.8% |
| MERCK & CO INC | 4 | Q3 2023 | 14.1% |
| ARGENX SE | 4 | Q3 2023 | 12.3% |
| LILLY ELI & CO | 4 | Q3 2023 | 14.5% |
| ABBVIE INC | 4 | Q3 2023 | 5.6% |
| ASTRAZENECA PLC | 4 | Q3 2023 | 5.4% |
| SEAGEN INC | 4 | Q3 2023 | 4.5% |
| BIOMARIN PHARMACEUTICAL INC | 4 | Q3 2023 | 4.3% |
| NEUROCRINE BIOSCIENCES INC | 4 | Q3 2023 | 2.1% |
| VERTEX PHARMACEUTICALS INC | 4 | Q3 2023 | 2.6% |
View Artia Global Partners LP's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2024-05-15 |
| 13F-HR | 2024-02-14 |
| 13F-HR | 2023-11-14 |
| 13F-HR | 2023-08-14 |
| 13F-HR | 2023-05-15 |
| 13F-HR | 2023-02-14 |
View Artia Global Partners LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.